Trial reportJPEN. Journal of parenteral and enteral nutrition2017
Low-Dose Parenteral Soybean Oil for the Prevention of Parenteral Nutrition-Associated Liver Disease in Neonates With Gastrointestinal Disorders.
Trial report in JPEN. Journal of parenteral and enteral nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Eligible Infants Included in Neonatal Clinical Trials and Reasons for Noninclusion: A Systematic Review.JAMA network open · 2024Pooled it
- Race and Ethnicity of Infants Enrolled in Neonatal Clinical Trials: A Systematic Review.JAMA network open · 2023Pooled it
- Lipid emulsions for parenterally fed term and late preterm infants.The Cochrane database of systematic reviews · 2019Pooled it
- Developmental outcomes after soybean oil vs mixed-oil intravenous lipid emulsions in neonates: A secondary analysis of a clinical trial.JPEN. Journal of parenteral and enteral nutrition · 2026Trial
- Two-Year Neurodevelopment and Growth Outcomes for Preterm Neonates Who Received Low-Dose Intravenous Soybean Oil.JPEN. Journal of parenteral and enteral nutrition · 2018Trial
- Pathogenesis and Management of Intestinal Failure-Associated Liver Disease.Seminars in liver disease · 2025Review
- Outcomes in preterm infants who received a lipid emulsion with fish oil: An observational study.JPEN. Journal of parenteral and enteral nutrition · 2023Observational
- Macronutrients and Micronutrients in Parenteral Nutrition for Preterm Newborns: A Narrative Review.Nutrients · 2022Review
- Review
- New Insights Into Intestinal Failure-Associated Liver Disease in Children.Hepatology (Baltimore, Md.) · 2020Review
- Neurotensin contributes to pediatric intestinal failure-associated liver disease via regulating intestinal bile acids uptake.EBioMedicine · 2018Article
- Intravenous Fish Oil and Pediatric Intestinal Failure-Associated Liver Disease: Changes in Plasma Phytosterols, Cytokines, and Bile Acids and Erythrocyte Fatty Acids.JPEN. Journal of parenteral and enteral nutrition · 2018Observational
- Characterization of Fatty Acid Profiles in Infants With Intestinal Failure-Associated Liver Disease.JPEN. Journal of parenteral and enteral nutrition · 2018Article
- Neonatal growth with fish oil or mixed oil lipid emulsions in intestinal failure associated liver disease.Intestinal Failure (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNeonates with gastrointestinal disorders (GDs) are at high risk for parenteral nutrition-associated liver disease (PNALD). Soybean-based intravenous lipid emulsions (S-ILE) have been associated with PNALD. This study's objective was to determine if a lower dose compared with a higher dose of S-ILE prevents cholestasis without compromising growth. MATERIALS AND
methodsThis multicenter randomized controlled pilot study enrolled patients with GDs who were ≤5 days of age to a low dose (~1 g/kg/d) (LOW) or control dose of S-ILE (~3 g/kg/d) (CON). The primary outcome was cholestasis (direct bilirubin [DB] >2 mg/dL) after the first 7 days of age. Secondary outcomes included growth, PN duration, and late-onset sepsis.
resultsBaseline characteristics were similar between the LOW (n = 20) and CON groups (n = 16). When the LOW group was compared with the CON group, there was no difference in cholestasis (30% vs 38%, P = .7) or secondary outcomes. However, mean ± SE DB rate of change over the first 8 weeks (0.07 ± 0.04 vs 0.3 ± 0.09 mg/dL/wk, P = .01) and entire study (0.008 ± 0.03 vs 0.2 ± 0.07 mg/dL/wk, P = .02) was lower in the LOW group compared with the CON group.
conclusionIn neonates with GDs who received a lower dose of S-ILE, DB increased at a slower rate in comparison to neonates who received a higher dose of S-ILE. Growth was comparable between the groups. This study demonstrates a need for a larger, randomized controlled trial comparing 2 different S-ILE doses for cholestasis prevention in neonates at risk for PNALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.